Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fosfluconazole→

Fosfluconazole Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
194798-83-9
Molecular formula
C13H13F2N6O4P
Molecular weight
386.25 g/mol
Drug class
Fluconazole prodrugtriazole antifungal
Mechanism of action
Fosfluconazole is hydrolysed to fluconazole, which inhibits fungal lanosterol 14-alpha-demethylase (CYP51), impairing ergosterol biosynthesis and fungal cell-membrane formation.
Indications / reported uses
  • Intravenous antifungal treatment or step-down therapy for systemic fungal infections susceptible to fluconazole where fosfluconazole formulations are authorised; exact indications depend on product and jurisdiction

Sources: NLM MeSH — Fosfluconazole · PubMed — Fosfluconazole prodrug conversion · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fosfluconazole Environmental Risk Assessment (ERA) (the Fosfluconazole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.